Free Trial

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 1.7% - Should You Sell?

Eupraxia Pharmaceuticals logo with Medical background
Remove Ads

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s stock price traded down 1.7% during trading on Monday . The stock traded as low as $4.18 and last traded at $4.08. 3,152 shares changed hands during trading, a decline of 81% from the average session volume of 16,604 shares. The stock had previously closed at $4.15.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on Eupraxia Pharmaceuticals in a report on Friday, February 21st. They set a "buy" rating and a $12.00 target price on the stock.

Get Our Latest Stock Report on EPRX

Eupraxia Pharmaceuticals Price Performance

The company has a market cap of $142.41 million and a P/E ratio of -5.55. The company has a fifty day simple moving average of $3.44 and a 200-day simple moving average of $3.08.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EPRX. Millennium Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $31,000. Raymond James Financial Inc. bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $37,000. Finally, Bank of Montreal Can increased its holdings in shares of Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after buying an additional 7,500 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

Featured Stories

Should You Invest $1,000 in Eupraxia Pharmaceuticals Right Now?

Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.

While Eupraxia Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

Flying cars are coming sooner than you think! Investors are getting excited about this futuristic industry, and MarketBeat analyst Chris Markoch breaks down 7 flying car stocks poised to take off.

Related Videos

Archer Aviation: Sinking Now, Soaring Soon?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
Palantir’s Explosive Growth: Buy Now or Wait for a Dip?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads